![\"genmab_logoa.jpg\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/05\/genmab_logoa.jpg\")
<\/p>\nUNITED STATES<\/p>\n
SECURITIES AND EXCHANGE COMMISSION<\/p>\n
Washington,\u00a0D.C. 20549<\/p>\n
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE\u00a013a-16 OR\u00a015d-16<\/p>\n
OF THE SECURITIES EXCHANGE ACT OF 1934<\/p>\n
FOR THE\u00a0MONTH OF MAY 2026<\/p>\n
COMMISSION FILE NUMBER 001-38976 <\/p>\n
Genmab A\/S
(Exact name of Registrant as specified in its charter)<\/p>\n
Carl Jacobsens Vej 30<\/p>\n
2500 Valby<\/p>\n
Denmark<\/p>\n
+45 70 20 27 28
(Address of principal executive offices)<\/p>\n
Indicate by check mark whether the registrant files or will file annual reports under cover Form\u00a020-F or\u00a0Form\u00a040-F.<\/p>\n
Form\u00a020-F\u00a0 Form\u00a040-F\u00a0<\/p>\n
This report on Form\u00a06-K\u00a0shall be deemed to be\u00a0incorporated by reference\u00a0in Genmab A\/S\u2019s registration statements on\u00a0Form\u00a0S-8\u00a0(File\u00a0No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505)\u00a0and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.<\/p>\n
EXHIBIT\u00a0INDEX<\/p>\n
ExhibitDescription of Exhibit99.1<\/p>\n
Company Announcement Dated May 29, 2026: Transactions with Shares and Linked Securities in Genmab A\/S Made by Managerial Employees and Their Closely Associated Persons<\/p>\n
SIGNATURE<\/p>\n
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<\/p>\n
GENMAB A\/SBY:\/s\/ Anthony PaganoName: Anthony PaganoTitle: Executive Vice President & Chief Financial Officer<\/p>\n
DATE: MAY 29, 2026<\/p>\n
Exhibit 99.1<\/p>\n
<\/p>\n
Transactions with Shares and Linked Securities in Genmab A\/S Made by Managerial Employees and Their Closely Associated Persons<\/p>\n
Company Announcement<\/p>\n
COPENHAGEN, Denmark; May 29, 2026 \u2013 Genmab A\/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596\/2014 on Market Abuse and Implementing Regulation 2016\/523, this document discloses the data of the transactions made in Genmab A\/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.<\/p>\n
The company\u2019s managerial employees and their closely associated persons have given Genmab A\/S power of attorney on their behalf to publish trading in Genmab shares by the company\u2019s managerial employees and their closely associated persons.<\/p>\n
Please find below a statement of such trading in shares issued by Genmab A\/S.<\/p>\n
1.Details of the person discharging managerial responsibilities \/ person closely associateda)NameMichael Kavanagh2.Reason for the notificationa)Position\/statusMember of the Board of Directorsb)Initial notification\/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameGenmab A\/Sb)LEI-code529900MTJPDPE4MHJ1224.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)<\/p>\n
Description of the financial instrument, type of instrument<\/p>\n
Identification code<\/p>\n
Share<\/p>\n
DK0010272202<\/p>\n
b)Nature of the transactionSale of sharesc)Price(s) and volume(s)Price(s)Volume(s)DKK1,734.75221DKK1,734.75305d)<\/p>\n
Aggregated information<\/p>\n
– Aggregated volume<\/p>\n
– Price<\/p>\n
526 shares<\/p>\n
DKK 1,734.75<\/p>\n
e)Date of the transaction2026-05-29f)Place of the transactionNASDAQ Copenhagen (XCSE)Genmab A\/S
Carl Jacobsens Vej 30
2500 Valby, DenmarkTel: +45 7020 2728
www.genmab.com<\/p>\n
Company Announcement no. 28<\/p>\n
Page 1\/2<\/p>\n
CVR no. 2102 3884<\/p>\n
LEI Code 529900MTJPDPE4MHJ122<\/p>\n
<\/p>\n
Transactions with Shares and Linked Securities in Genmab A\/S Made by Managerial Employees and Their Closely Associated Persons<\/p>\n
About Genmab <\/p>\n
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody\u2013drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab\u2019s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.<\/p>\n
\u00a0<\/p>\n
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com\u202fand follow us on LinkedIn and X.<\/p>\n
Contact:\u00a0\u00a0\u00a0\u00a0
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs<\/p>\n
T: +1 609 524 0065; E: mmp@genmab.com<\/p>\n
Andrew Carlsen, Vice President, Head of Investor Relations<\/p>\n
T: +45 3377 9558; E: acn@genmab.com <\/p>\n
The Company Announcement contains forward looking statements. The words \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend\u201d and \u201cplan\u201d and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab\u2019s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab\u2019s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. <\/p>\n
Genmab A\/S and\/or its subsidiaries own the following trademarks: Genmab\u00ae; the Y-shaped Genmab logo\u00ae; Genmab in combination with the Y-shaped Genmab logo\u00ae; HuMax\u00ae; DuoBody\u00ae; HexaBody\u00ae; DuoHexaBody\u00ae, HexElect\u00ae and KYSO\u00ae.<\/p>\n
Genmab A\/S
Carl Jacobsens Vej 30
2500 Valby, DenmarkTel: +45 7020 2728
www.genmab.com<\/p>\n
Company Announcement no. 28<\/p>\n
Page 2\/2<\/p>\n
CVR no. 2102 3884<\/p>\n
LEI Code 529900MTJPDPE4MHJ122<\/p>\n","protected":false},"excerpt":{"rendered":"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,\u00a0D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE\u00a013a-16 OR\u00a015d-16 OF…\n","protected":false},"author":2,"featured_media":95680,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[6],"tags":[2759,108,49809,31511,12495,49808,33486,32355,15708],"class_list":["post-95679","post","type-post","status-publish","format-standard","has-post-thumbnail","category-copenhagen","tag-biotechnology","tag-copenhagen","tag-director-share-sale","tag-form-6-k","tag-genmab","tag-gmab","tag-insider-transaction","tag-market-abuse-regulation","tag-nasdaq-copenhagen"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116665339613622195","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/95679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=95679"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/95679\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/95680"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=95679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=95679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=95679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}